Plasma and urinary excretion kinetics of oral baclofen in healthy subjects
Baclofen, a centrally acting muscle relaxant, is used in the treatment of spasticity. Its pharmacokinetics has been derived from plasma and urine data in four healthy subjects, whose renal function was simultaneously measured. After oral administration of a single 40 mg dose, baclofen was mainly exc...
Gespeichert in:
Veröffentlicht in: | European journal of clinical pharmacology 1989-03, Vol.37 (2), p.181-184 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 184 |
---|---|
container_issue | 2 |
container_start_page | 181 |
container_title | European journal of clinical pharmacology |
container_volume | 37 |
creator | WUIS, E. W DIRKS, M. J. M TERMOND, E. E. S VREE, T. B VAN DER KLEIJN, E |
description | Baclofen, a centrally acting muscle relaxant, is used in the treatment of spasticity. Its pharmacokinetics has been derived from plasma and urine data in four healthy subjects, whose renal function was simultaneously measured. After oral administration of a single 40 mg dose, baclofen was mainly excreted unchanged by the kidney, 69 (14)%. The half-life, calculated from extended least squares modelling (ELSMOS) both of plasma and urine data was 6.80 (0.68) h, which is longer than reported in most studies based solely on plasma data. The renal excretion rate constant had the high mean value of 0.35 (0.24) h-1, and the apparent renal clearance of baclofen equalled the creatinine clearance. Passive tubular reabsorption is relatively unimportant, since no dependence was observed on variables urine flow or pH. Although active tubular secretion may contribute to its renal clearance, as shown by the effect of co-administration of probenecid, glomerular filtration appears to be the dominant transport mechanism. |
doi_str_mv | 10.1007/bf00558228 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79228875</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>79228875</sourcerecordid><originalsourceid>FETCH-LOGICAL-c377t-dcd5176b5e7b69a4b5149b885de4bc0686428fa5ef8cfb79d002fe2efa5dd0e13</originalsourceid><addsrcrecordid>eNo9kM1Lw0AUxBdRaq1evAt7EA9C9O0mm90ctVg_KOhBz2E_3tLUNNHdBOx_b6Sxpze8-TEwQ8g5gxsGIG-NBxBCca4OyJRlKU8YZOyQTAFSluSFhGNyEuMagIkC0gmZcFlwJtMpeXmrddxoqhtH-1A1Omwp_tiAXdU29LNqBmEjbT1tg66p0bZuPTa0augKdd2ttjT2Zo22i6fkyOs64tl4Z-Rj8fA-f0qWr4_P87tlYlMpu8RZJ5jMjUBp8kJnRrCsMEoJh5mxkKs848prgV5Zb2ThALhHjsPLOUCWzsjVLvcrtN89xq7cVNFiXesG2z6WQzWulBQDeL0DbWhjDOjLr1BthoYlg_JvuPJ-8T_cAF-Mqb3ZoNuj41KDfzn6Olpd-6AbW8U9lktZiEylv4yNdZY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79228875</pqid></control><display><type>article</type><title>Plasma and urinary excretion kinetics of oral baclofen in healthy subjects</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>WUIS, E. W ; DIRKS, M. J. M ; TERMOND, E. E. S ; VREE, T. B ; VAN DER KLEIJN, E</creator><creatorcontrib>WUIS, E. W ; DIRKS, M. J. M ; TERMOND, E. E. S ; VREE, T. B ; VAN DER KLEIJN, E</creatorcontrib><description>Baclofen, a centrally acting muscle relaxant, is used in the treatment of spasticity. Its pharmacokinetics has been derived from plasma and urine data in four healthy subjects, whose renal function was simultaneously measured. After oral administration of a single 40 mg dose, baclofen was mainly excreted unchanged by the kidney, 69 (14)%. The half-life, calculated from extended least squares modelling (ELSMOS) both of plasma and urine data was 6.80 (0.68) h, which is longer than reported in most studies based solely on plasma data. The renal excretion rate constant had the high mean value of 0.35 (0.24) h-1, and the apparent renal clearance of baclofen equalled the creatinine clearance. Passive tubular reabsorption is relatively unimportant, since no dependence was observed on variables urine flow or pH. Although active tubular secretion may contribute to its renal clearance, as shown by the effect of co-administration of probenecid, glomerular filtration appears to be the dominant transport mechanism.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/bf00558228</identifier><identifier>PMID: 2792173</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Adult ; Baclofen - blood ; Baclofen - pharmacokinetics ; Baclofen - urine ; Biological and medical sciences ; Chromatography, High Pressure Liquid ; Female ; Humans ; Hydrogen-Ion Concentration ; Male ; Medical sciences ; Muscle ; Pharmacology. Drug treatments ; Reference Values ; Spectrometry, Fluorescence ; Spectrophotometry, Ultraviolet</subject><ispartof>European journal of clinical pharmacology, 1989-03, Vol.37 (2), p.181-184</ispartof><rights>1990 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c377t-dcd5176b5e7b69a4b5149b885de4bc0686428fa5ef8cfb79d002fe2efa5dd0e13</citedby><cites>FETCH-LOGICAL-c377t-dcd5176b5e7b69a4b5149b885de4bc0686428fa5ef8cfb79d002fe2efa5dd0e13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=6779548$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2792173$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WUIS, E. W</creatorcontrib><creatorcontrib>DIRKS, M. J. M</creatorcontrib><creatorcontrib>TERMOND, E. E. S</creatorcontrib><creatorcontrib>VREE, T. B</creatorcontrib><creatorcontrib>VAN DER KLEIJN, E</creatorcontrib><title>Plasma and urinary excretion kinetics of oral baclofen in healthy subjects</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><description>Baclofen, a centrally acting muscle relaxant, is used in the treatment of spasticity. Its pharmacokinetics has been derived from plasma and urine data in four healthy subjects, whose renal function was simultaneously measured. After oral administration of a single 40 mg dose, baclofen was mainly excreted unchanged by the kidney, 69 (14)%. The half-life, calculated from extended least squares modelling (ELSMOS) both of plasma and urine data was 6.80 (0.68) h, which is longer than reported in most studies based solely on plasma data. The renal excretion rate constant had the high mean value of 0.35 (0.24) h-1, and the apparent renal clearance of baclofen equalled the creatinine clearance. Passive tubular reabsorption is relatively unimportant, since no dependence was observed on variables urine flow or pH. Although active tubular secretion may contribute to its renal clearance, as shown by the effect of co-administration of probenecid, glomerular filtration appears to be the dominant transport mechanism.</description><subject>Adult</subject><subject>Baclofen - blood</subject><subject>Baclofen - pharmacokinetics</subject><subject>Baclofen - urine</subject><subject>Biological and medical sciences</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Female</subject><subject>Humans</subject><subject>Hydrogen-Ion Concentration</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Muscle</subject><subject>Pharmacology. Drug treatments</subject><subject>Reference Values</subject><subject>Spectrometry, Fluorescence</subject><subject>Spectrophotometry, Ultraviolet</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1989</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kM1Lw0AUxBdRaq1evAt7EA9C9O0mm90ctVg_KOhBz2E_3tLUNNHdBOx_b6Sxpze8-TEwQ8g5gxsGIG-NBxBCca4OyJRlKU8YZOyQTAFSluSFhGNyEuMagIkC0gmZcFlwJtMpeXmrddxoqhtH-1A1Omwp_tiAXdU29LNqBmEjbT1tg66p0bZuPTa0augKdd2ttjT2Zo22i6fkyOs64tl4Z-Rj8fA-f0qWr4_P87tlYlMpu8RZJ5jMjUBp8kJnRrCsMEoJh5mxkKs848prgV5Zb2ThALhHjsPLOUCWzsjVLvcrtN89xq7cVNFiXesG2z6WQzWulBQDeL0DbWhjDOjLr1BthoYlg_JvuPJ-8T_cAF-Mqb3ZoNuj41KDfzn6Olpd-6AbW8U9lktZiEylv4yNdZY</recordid><startdate>198903</startdate><enddate>198903</enddate><creator>WUIS, E. W</creator><creator>DIRKS, M. J. M</creator><creator>TERMOND, E. E. S</creator><creator>VREE, T. B</creator><creator>VAN DER KLEIJN, E</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198903</creationdate><title>Plasma and urinary excretion kinetics of oral baclofen in healthy subjects</title><author>WUIS, E. W ; DIRKS, M. J. M ; TERMOND, E. E. S ; VREE, T. B ; VAN DER KLEIJN, E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c377t-dcd5176b5e7b69a4b5149b885de4bc0686428fa5ef8cfb79d002fe2efa5dd0e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1989</creationdate><topic>Adult</topic><topic>Baclofen - blood</topic><topic>Baclofen - pharmacokinetics</topic><topic>Baclofen - urine</topic><topic>Biological and medical sciences</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Female</topic><topic>Humans</topic><topic>Hydrogen-Ion Concentration</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Muscle</topic><topic>Pharmacology. Drug treatments</topic><topic>Reference Values</topic><topic>Spectrometry, Fluorescence</topic><topic>Spectrophotometry, Ultraviolet</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WUIS, E. W</creatorcontrib><creatorcontrib>DIRKS, M. J. M</creatorcontrib><creatorcontrib>TERMOND, E. E. S</creatorcontrib><creatorcontrib>VREE, T. B</creatorcontrib><creatorcontrib>VAN DER KLEIJN, E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WUIS, E. W</au><au>DIRKS, M. J. M</au><au>TERMOND, E. E. S</au><au>VREE, T. B</au><au>VAN DER KLEIJN, E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma and urinary excretion kinetics of oral baclofen in healthy subjects</atitle><jtitle>European journal of clinical pharmacology</jtitle><addtitle>Eur J Clin Pharmacol</addtitle><date>1989-03</date><risdate>1989</risdate><volume>37</volume><issue>2</issue><spage>181</spage><epage>184</epage><pages>181-184</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>Baclofen, a centrally acting muscle relaxant, is used in the treatment of spasticity. Its pharmacokinetics has been derived from plasma and urine data in four healthy subjects, whose renal function was simultaneously measured. After oral administration of a single 40 mg dose, baclofen was mainly excreted unchanged by the kidney, 69 (14)%. The half-life, calculated from extended least squares modelling (ELSMOS) both of plasma and urine data was 6.80 (0.68) h, which is longer than reported in most studies based solely on plasma data. The renal excretion rate constant had the high mean value of 0.35 (0.24) h-1, and the apparent renal clearance of baclofen equalled the creatinine clearance. Passive tubular reabsorption is relatively unimportant, since no dependence was observed on variables urine flow or pH. Although active tubular secretion may contribute to its renal clearance, as shown by the effect of co-administration of probenecid, glomerular filtration appears to be the dominant transport mechanism.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>2792173</pmid><doi>10.1007/bf00558228</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0031-6970 |
ispartof | European journal of clinical pharmacology, 1989-03, Vol.37 (2), p.181-184 |
issn | 0031-6970 1432-1041 |
language | eng |
recordid | cdi_proquest_miscellaneous_79228875 |
source | MEDLINE; SpringerLink Journals |
subjects | Adult Baclofen - blood Baclofen - pharmacokinetics Baclofen - urine Biological and medical sciences Chromatography, High Pressure Liquid Female Humans Hydrogen-Ion Concentration Male Medical sciences Muscle Pharmacology. Drug treatments Reference Values Spectrometry, Fluorescence Spectrophotometry, Ultraviolet |
title | Plasma and urinary excretion kinetics of oral baclofen in healthy subjects |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T21%3A18%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20and%20urinary%20excretion%20kinetics%20of%20oral%20baclofen%20in%20healthy%20subjects&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=WUIS,%20E.%20W&rft.date=1989-03&rft.volume=37&rft.issue=2&rft.spage=181&rft.epage=184&rft.pages=181-184&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/bf00558228&rft_dat=%3Cproquest_cross%3E79228875%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79228875&rft_id=info:pmid/2792173&rfr_iscdi=true |